D-0320-2021 Class II Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-0320-2021 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Mar 15, 2021 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Jun 6, 2023). Affected quantity: 91,211 syringes.

Recall details

Product Type
Drugs
Report Date
Apr 14, 2021
Initiation Date
Mar 15, 2021
Termination Date
Jun 6, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
91,211 syringes

Product description

Ganirelix Acetate Injection, 250 mcg/0.5 mL, Sterile Prefilled Syringe, Rx only, Distributor: Ferring Pharmaceuticals, Inc., Parsippany, NJ 07054 USA, Manufactured by: Sun Pharmaceutical Industries Ltd, Halol, Gujarat, India Made in India, NDC 55566-1000-1.

Reason for recall

Failed Impurities/Degradation Specifications

Distribution pattern

NJ

Code information

Lots JKU1212A, JKU1503A, JKU1504A, JKU1505A, JKU1506A, Exp 03/2021; JKU3313A & JKU3314A, Exp 08/2021.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0320-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0320-2021. Report a data issue: hello@regdatalab.com.